home · filing · 0001193125-22-079036
8-K filed March 18, 2022, 7:59 PM ET
ticker FBRX
CIK 0001419041
leadership
confidence high
sentiment neutral
materiality 0.30
Forte Biosciences appoints Barbara K. Finck, M.D. to Board of Directors
Forte Biosciences, Inc.
Appointment effective March 16, 2022; Dr. Finck will serve as a Class I director until 2024 annual meeting.
Annual cash retainer of $40,000, paid quarterly in arrears on a pro-rata basis.
Granted option for 50,000 shares of common stock vesting monthly over three years.
Dr. Finck currently acting Chief Medical Officer at Coherus BioSciences; prior CMO at NKT Therapeutics and Osprey Pharmaceuticals.
No arrangement with any other person for election; no family relationships with directors or officers.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2022-03-16
Filed March 18, 2022, 7:59 PM ET
appointed Barbara K. Finck, M.D. to the Board, effective March 16, 2022.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Barbara K. Finck, M.D. was appointed as Director at Forte Biosciences, Inc..
Action appointed
Role Director
Exact text from the filing
appointed Barbara K. Finck, M.D. to the Board, effective March 16, 2022.
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-22-079036
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.